Graham Smith, Ph.D.

Graham Smith

The Institute of Cancer Research, London, UK.

 

  • Biography
  • Research Interests
  • Publications

Dr. Graham Smith trained as a synthetic organic chemist, receiving a Ph.D. from the University of Surrey. Subsequent to this he carried out postdoctoral research at Newcastle University, working on the synthesis and evaluation of diaryliodonium salts for use in PET radiochemistry. From there he moved to Imperial College Faculty of Medicine to work on the development of new PET imaging agents for use in cancer (in collaboration with Hammersmith Imanet).

In 2011, Dr. Smith moved to the University of Hull as Lecturer in Molecular Imaging where he helped to establish a new PET research facility. In 2013, he moved to the Institute of Cancer Research to lead radiochemistry development within the Division of Radiotherapy and Imaging.  His research interests include imaging cancer metabolism, acquired resistance to therapy, development of new PET and radiotherapy agents and the investigation of new radiochemistry methodology.

My research encompasses the investigation of fluorine-18 radiochemistry methodology through to clinical translation of new PET probes and GMP grade production of PET radiopharmaceuticals. The main focus of my research is the synthesis and evaluation of new PET probes for cancer imaging, with an emphasis on areas such as early diagnosis, patient stratification and quantification of treatment response.

Kaliszczak, M., Patel, H., Kroll, SH., Carroll, L., Smith, G., Delaney, S., Heathcote, DA., Bondke, A., Fuchter, MJ., Coombes, RC., et al. (2013) Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance. Br J Cancer, Vol.109(9), pp.2356-2367.

Nguyen, QD., Lavdas, I., Gubbins, J., Smith, G., Fortt, R., Carroll, LS., Graham, MA. & Aboagye, EO. (2013) Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging. Clin Cancer Res, Vol.19(14), pp.3914-3924.

Tietz, O., Kamaly, N., Smith, G., Shamsaei, E., Bhakoo, KK., Long, NJ. & Aboagye, EO. (2013) Design, synthesis and in vitro characterization of fluorescent and paramagnetic CXCR4-targeted imaging agents. Am J Nucl Med Mol Imaging, Vol.3(4), pp.372-383.

Smith, G., Carroll, L. & Aboagye, EO. (2012) New Frontiers in the Design and Synthesis of Imaging Probes for PET Oncology: Current Challenges and Future Directions MOLECULAR IMAGING AND BIOLOGY, Vol.14(6), pp.653-666.

Fortt, R., Smith, G., Awais, RO., Luthra, SK. & Aboagye, EO. (2012) Automated GMP Synthesis of [F-18]ICMT-11 for In Vivo Imaging of Caspase-3 Activity NUCLEAR MEDICINE AND BIOLOGY, Vol.39(7).

Smith, G., Sala, R., Carroll, L., Behan, K., Glaser, M., Robins, E., Nguyen, QD. & Aboagye, EO. (2012) Synthesis and evaluation of nucleoside radiotracers for imaging proliferation. Nucl Med Biol, Vol.39(5), pp.652-665.

Aberg, O., Pisaneschi, F., Smith, G., Nguyen, Q-D., Stevens, E. & Aboagye, EO. (2012) F-18-labelling of a cyclic pentapeptide inhibitor of the chemokine receptor CXCR4 JOURNAL OF FLUORINE CHEMISTRY, Vol.135 pp.200-206.

Nguyen, Q-D., Challapalli, A., Smith, G., Fortt, R., Aboagye, EO. & Consortium, Q-C. (2012) Imaging apoptosis with positron emission tomography: ‘Bench to bedside’ development of the caspase-3/7 specific radiotracer [F-18]ICMT-11 EUROPEAN JOURNAL OF CANCER, Vol.48(4), pp.432-440.

Witney, TH., Alam, IS., Turton, DR., Smith, G., Carroll, L., Brickute, D., Twyman, FJ., Nguyen, Q-D., Tomasi, G., Awais, RO., et al. (2012) Evaluation of Deuterated F-18- and C-11-Labeled Choline Analogs for Cancer Detection by Positron Emission Tomography CLINICAL CANCER RESEARCH, Vol.18(4), pp.1063-1072.

Evans, HL., Slade, RL., Carroll, L., Smith, G., Nguyen, QD., Iddon, L., Kamaly, N., Stöckmann, H., Leeper, FJ., Aboagye, EO., et al. (2012) Copper-free click–a promising tool for pre-targeted PET imaging. Chem Commun (Camb), Vol.48(7).

Glaser, M., Goggi, J., Smith, G., Morrison, M., Luthra, SK., Robins, E. & Aboagye, EO. (2011) Improved radiosynthesis of the apoptosis marker F-18-ICMT11 including biological evaluation BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, Vol.21(23), pp.6945-6949.

Smith, G., Zhao, Y., Leyton, J., Shan, B., Nguyen, QD., Perumal, M., Turton, D., Årstad, E., Luthra, SK., Robins, EG., et al. (2011) Radiosynthesis and pre-clinical evaluation of [(18)F]fluoro-[1,2-(2)H(4)]choline. Nucl Med Biol, Vol.38(1), pp.39-51.

Pisaneschi, F., Nguyen, QD., Shamsaei, E., Glaser, M., Robins, E., Kaliszczak, M., Smith, G., Spivey, AC. & Aboagye, EO. (2010) Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: synthesis and biological evaluation. Bioorg Med Chem, Vol.18(18), pp.6634-6645.

Smith, G., Nguyen, QD. & Aboagye, EO. (2009) Translational imaging of apoptosis. Anticancer Agents Med Chem, Vol.9(9), pp.958-967.

Leyton, J., Smith, G., Zhao, Y., Perumal, M., Nguyen, Q-D., Robins, E., Arstad, E. & Aboagye, EO. (2009) [F-18]Fluoromethyl-[1,2-H-2(4)]-Choline: A Novel Radiotracer for Imaging Choline Metabolism in Tumors by Positron Emission Tomography CANCER RESEARCH, Vol.69(19), pp.7721-7728.

Nguyen, QD., Smith, G., Glaser, M., Perumal, M., Arstad, E. & Aboagye, EO. (2009) Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci U S A, Vol.106(38), pp.16375-16380.

Smith, G., Glaser, M., Perumal, M., Nguyen, QD., Shan, B., Arstad, E. & Aboagye, EO. (2008) Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F]fluoroethylazide. J Med Chem, Vol.51(24), pp.8057-8067.

Leyton, J., Smith, G., Lees, M., Perumal, M., Nguyen, QD., Aigbirhio, FI., Golovko, O., He, QM., Workman, P. & Aboagye, EO. (2008) Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901 MOL CANCER THER, Vol.7(9), pp.3112-3121.